Holen Sie sich die Stockscreener-App
9.66
3.40%
-0.34
Vorhandelsmarkt:
9.96
0.30
+3.11%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt GRFS?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$10.00
Offen:
$9.94
24-Stunden-Volumen:
1.35M
Relative Volume:
1.57
Marktkapitalisierung:
$2.53B
Einnahmen:
$7.94B
Nettoeinkommen (Verlust:
$225.54M
KGV:
29.28
EPS:
0.3299
Netto-Cashflow:
$709.16M
1W Leistung:
-1.13%
1M Leistung:
+10.15%
6M Leistung:
+30.54%
1J Leistung:
+22.59%
1-Tages-Spanne:
$9.66
$10.00
1-Wochen-Bereich:
$9.66
$10.30
52-Wochen-Spanne:
$6.19
$10.30
Grifols Sa Adr Stock (GRFS) Company Profile
Vergleichen Sie GRFS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GRFS
Grifols Sa Adr
|
9.66 | 6.65B | 7.94B | 225.54M | 709.16M | 0.3299 |
|
LLY
Lilly Eli Co
|
776.44 | 692.83B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
167.93 | 373.35B | 90.63B | 22.66B | 18.57B | 9.35 |
|
ABBV
Abbvie Inc
|
187.11 | 329.24B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
116.83 | 231.66B | 55.19B | 13.65B | 16.81B | 6.86 |
|
NVO
Novo Nordisk Adr
|
66.78 | 298.68B | 43.59B | 15.04B | 10.74B | 3.3766 |
Grifols Sa Adr Stock (GRFS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-12 | Fortgesetzt | Morgan Stanley | Overweight |
| 2024-03-12 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-04-12 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-03 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-16 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2023-01-18 | Hochstufung | Jefferies | Hold → Buy |
| 2022-04-08 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-11-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-10-19 | Herabstufung | Barclays | Overweight → Underweight |
| 2021-10-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-06-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2021-04-20 | Eingeleitet | Deutsche Bank | Hold |
| 2021-03-23 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-03-11 | Hochstufung | HSBC Securities | Hold → Buy |
| 2020-10-01 | Hochstufung | Citigroup | Sell → Neutral |
| 2020-06-09 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-06-09 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-03-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-06-27 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-02-08 | Herabstufung | Berenberg | Buy → Hold |
| 2018-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2018-06-01 | Eingeleitet | Barclays | Overweight |
| 2017-10-31 | Eingeleitet | Citigroup | Buy |
| 2017-06-30 | Herabstufung | Goldman | Buy → Neutral |
| 2017-04-06 | Eingeleitet | BofA/Merrill | Buy |
| 2017-01-03 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2016-02-09 | Hochstufung | Berenberg | Hold → Buy |
| 2016-01-04 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2015-12-02 | Herabstufung | HSBC Securities | Buy → Hold |
| 2015-11-20 | Herabstufung | Berenberg | Buy → Hold |
| 2015-04-28 | Herabstufung | Berenberg | Buy → Hold |
Alle ansehen
Grifols Sa Adr Aktie (GRFS) Neueste Nachrichten
Oppenheimer Asset Management Inc. Acquires 23,980 Shares of Grifols, S.A. (NASDAQ:GRFS) - Defense World
ADMA Biologics Vs. Grifols: Which Plasma Therapy Stock Is The Better Buy? - Barchart.com
Grifols: If This Works Out, It Has Massive Upside (NASDAQ:GRFS) - Seeking Alpha
Grifols S.A. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
SMRT’s latest rating updates from top analysts. - knoxdaily.com
Investing in Grifols SA ADR (GRFS): What You Must Know - knoxdaily.com
Investing in Apellis Pharmaceuticals Inc (APLS) Is Getting More Attractive - knoxdaily.com
A company insider recently sold 10,000 shares of News Corp [NWSA]. Should You also Consider to Sale? - knoxdaily.com
Raymond James Downgrades Truist Financial Corporation (TFC) to a Mkt perform from an Outperform - knoxdaily.com
AT&T, Inc (T) rating upgrades by Exane BNP Paribas - knoxdaily.com
Grifols SA ADR (GRFS) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
Lazard Inc (LAZ) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Can Verra Mobility Corp Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
RYAN’s Market Whiplash: 0.32% YTD Rise, -10.03% Plunge in 30 Days - investchronicle.com
A significant driver of top-line growth: Grifols SA ADR (GRFS) - Sete News
SpringWorks Therapeutics Inc (SWTX) Stock: From Low to High in 52 Weeks - investchronicle.com
There is no doubt that Coeur Mining Inc (CDE) ticks all the boxes. - Sete News
GRFS (Grifols SA ADR) may reap gains as insiders became active recently - knoxdaily.com
BHP’s latest rating updates from top analysts. - knoxdaily.com
FHN’s latest rating updates from top analysts. - knoxdaily.com
Lake Street’s latest rating for ORGO stock - knoxdaily.com
Fox Corporation [FOX] stock was sold by MURDOCH KEITH RUPERT at the price of US$3.08 million - knoxdaily.com
6 undervalued stocks with low beta - Morningstar
Deutsche Bank raises Grifols SA price target to EUR11.00 - Investing.com India
Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale (GRFS) - Seeking Alpha
Get in on Grifols SA ADR’s (GRFS) buy-in window today! - SETE News
Wall Street analysts’ outlook for Douglas Elliman Inc (DOUG) - SETE News
Financial Metrics Exploration: Understanding Accuray Inc (ARAY) Through Ratios - The Dwinnex
Financial Fitness Check: Examining Mannkind Corp (MNKD)’s Key Ratios - The Dwinnex
Orphan Designated Drugs Market Analysis: Key Trends, Players and Forecasts for Future Growth - GlobeNewswire Inc.
Grifols: More Attractive Than In A Very Long Time (NASDAQ:GRFS) - Seeking Alpha
Grifols Stock Declines After Brookfield Drops Buyout Offer - Yahoo Finance
Brookfield Drops $6.8 Billion Offer to Buy Drugmaker Grifols - BNN Bloomberg
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% - Yahoo Finance
Grifols slips as board rebuffs Brookfield’s $6.8B offer (update) - MSN
Grifols stock slips as Brookfield offer rebuffed (GRFS:NASDAQ) - Seeking Alpha
Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down (NASDAQ:GRFS) - Seeking Alpha
UK Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
The UAE Blood Transfusion Diagnostics Market Size & Outlook, 2027 - Grand View Research
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday - Yahoo Finance
Grifols shares up on potential takeover by Brookfield - Investing.com
China Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
India Blood Transfusion Diagnostics Market Size & Outlook, 2027 - Grand View Research
Grifols: Going Private? Brookfield On The Scene (OTCMKTS:GIFLF) - Seeking Alpha
Grifols 2023 Annual Report on Form 20-F filed with the SEC - PR Newswire
Grifols S.A. (GRFS – ADR ADR Class B) Shares Decline Again After Gotham City Research Issues Another Critical Report – Hagens Berman - ACCESS Newswire
AMBAR, an Encouraging Alzheimer's Trial That Raises Questions - Frontiers
The 10 Most-Bought and Most-Sold European Stocks - Morningstar
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? - Yahoo Finance
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Grifols, S.A. - GlobeNewswire
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Grifols, - GlobeNewswire
Finanzdaten der Grifols Sa Adr-Aktie (GRFS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):